Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by biotech doyen John Maraganore, and additional cash for Purespring, Judo Bio, GEMMABio, and Basecamp Research.Cambridge, Massachusetts-based City Therapeutics emerged from the shadows with a $135 million Series A – led by ARCH Venture Partners – that will fund the development of a small interfering RNA (siRNA) drug discovery engine that the company thinks can deliver 'new-generation' drugs with improved potency and specificity and which can be delivered to a wider range of tissue types.Former Alnylam chief executive Maraganore, who will serve as executive chair of the new company, said his vision is that RNAi drugs will become 'the next major category of high-impact medicines, rivalling if not exceeding the success of monoclonal antibodies.' City expects to take its first candidate into the clinic around the end of next year.Also participating in the round were Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, and AN Ventures, amongst others.Purespring Therapeutics raised £80 million ($105 million) in second-round financing that will help the London, UK-based company bring its PS-002 adeno-associated viral (AAV) gene therapy for kidney disease IgA nephropathy (IgAN) into phase 1/2 clinical testing.

我们对最近生物技术融资的总结显示，City Therapeutics首轮表现强劲，这是一家由biotech doyen John Maraganore领导的新RNAi企业，Purespring、Judo Bio、GEMMABio和Basecamp Research获得了额外资金。总部位于马萨诸塞州剑桥市的城市治疗公司（City Therapeutics）以1.35亿美元的a系列（由ARCH Venture Partners牵头）从阴影中脱颖而出，该系列将资助开发一种小干扰RNA（siRNA）药物发现引擎，该公司认为该引擎可以提供具有改进效力和特异性的“新一代”药物，并且可以提供给更广泛的组织类型。将担任新公司执行主席的前Alnylam首席执行官马拉加诺尔（Maraganore）表示，他的愿景是RNAi药物将成为“下一大类高影响力药物，即使不超过单克隆抗体的成功率，也将与之匹敌。”曼城预计在明年年底左右将其第一位候选人送入诊所。参与本轮谈判的还有富达管理与研究公司、Invus、Slate Path Capital、Rock Springs Capital、Regeneron Ventures和AN Ventures等。Purespring Therapeutics在第二轮融资中筹集了8000万英镑（1.05亿美元），这将帮助这家总部位于英国伦敦的公司将其针对肾脏疾病IgA肾病（IgAN）的PS-002腺相关病毒（AAV）基因治疗纳入1/2期临床测试。

It follows a £45 million Series A that was completed in 2021.The company focuses on complement-mediated kidney diseases and also has preclinical-stage programmes in nephrotic syndrome and an undisclosed glomerular kidney disease. It reported preclinical results with its AAV platform earlier this year, demonstrating its ability to deliver genes to podocytes, specialised epithelial cells in the kidney .

该公司于2021年完成了价值4500万英镑的a系列。该公司专注于补体介导的肾脏疾病，并且还针对肾病综合征和未公开的肾小球疾病进行了临床前阶段的计划。今年早些时候，它报道了其AAV平台的临床前结果，证明了其将基因传递给足细胞（肾脏中的特殊上皮细胞）的能力。